Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

The company launched new products like WINREVAIR and CAPVAXIVE, which are performing well and have significant commercial potential. Merck & Co Inc (NYSE:MRK) has a diversified pipeline with more ...

According to the company, sales growth was primarily due to increased usage of KEYTRUDA globally, contributions from new launches, including WINREVAIR and CAPVAXIVE, and strong growth in Merck’s ...

Sales growth in the third quarter of 2024 was primarily due to increased usage of KEYTRUDA globally, contributions from new launches, including WINREVAIR and CAPVAXIVE, and strong growth in Merck ...

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more ...

CAPVAXIVE is Merck's approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck CEO Rob Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Meanwhile, in the U.S., the company’s pneumococcal conjugate vaccine Capvaxive recently scored a key ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024.